Targets › LIPC
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2026.
Catalyzes the hydrolysis of triglycerides and phospholipids present in circulating plasma lipoproteins, including chylomicrons, intermediate density lipoproteins (IDL), low density lipoproteins (LDL) of large size and high density lipoproteins (HDL), releasing free fatty acids (FFA) and smaller lipoprotein particles. Also exhibits lysophospholipase activity (By similarity). (UniProt, P11150)
Open in Phaseline: the race on LIPC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Icosapent ethyl Omega-3 fatty acid; increases HDL, reduces triglycerides | LIPC | Phase 2 | Aortic Valve Stenosis | Dec 2026 |
Aortic Valve Stenosis (1)
small molecule (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.